Can you provide the last earnings date for CRISPR THERAPEUTICS AG?
CRISPR THERAPEUTICS AG (CRSP) last reported earnings on 2/12/2026.
NASDAQ:CRSP • CH0334081137
Past quarterly earnings results for CRISPR THERAPEUTICS AG (CRSP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.37 | -1.17 | -16.65% | -211.36% | 864K | 4.327M | -80.03% | -97.58% |
| Q3 2025 | -1.17 | -1.28 | 8.57% | -15.84% | 889K | 9.082M | -90.21% | 47.67% |
| Q2 2025 | -1.29 | -1.45 | 11.00% | 13.42% | 892K | 6.38M | -86.02% | 72.53% |
| Q1 2025 | -1.58 | -1.28 | -23.86% | -10.49% | 865K | 6.628M | -86.95% | 71.63% |
| Q4 2024 | -0.44 | -1.19 | 63.08% | -140.00% | 35.691M | 8.044M | 343.70% | -82.26% |
| Q3 2024 | -1.01 | -1.45 | 30.41% | 28.37% | 602K | 6.944M | -91.33% | - |
| Q2 2024 | -1.49 | -1.55 | 4.06% | -52.04% | 517K | 3.609M | -85.67% | -99.26% |
| Q1 2024 | -1.43 | -1.36 | -5.19% | -113.43% | 504K | 27.076M | -98.14% | -99.50% |
| Q4 2023 | 1.10 | -0.07 | 1,593.05% | 178.01% | 201.206M | 134.27M | 49.85% | - |
| Q3 2023 | -1.41 | -1.99 | 29.13% | 37.05% | 8.117M | -100.00% | -100.00% | |
| Q2 2023 | -0.98 | -2.16 | 54.63% | 59.17% | 70M | 1.742M | 3,918.37% | 34,900.00% |
| Q1 2023 | -0.67 | -1.74 | 61.43% | 71.12% | 100M | 23.44M | 326.62% | 11,011.11% |
| Q4 2022 | -1.41 | -2.35 | 39.87% | 23.37% | 7.265M | -100.00% | -100.00% | |
| Q3 2022 | -2.24 | -2.34 | 4.11% | -34.13% | 100K | 1.649M | -93.94% | -87.50% |
| Q2 2022 | -2.40 | -2.27 | -5.64% | -125.42% | 200K | 2.105M | -90.50% | -99.98% |
| Q1 2022 | -2.32 | -1.98 | -17.46% | -53.64% | 900K | 2.82M | -68.09% | 80.00% |
| Q4 2021 | -1.84 | -1.80 | -1.98% | -22.67% | 12.9M | 2.318M | 456.51% | 3,125.00% |
| Q3 2021 | -1.67 | -1.79 | 6.77% | -26.52% | 800K | 1.145M | -30.13% | 700.00% |
| Q2 2021 | 9.44 | 3.59 | 162.72% | 826.15% | 900.7M | 429.34M | 109.79% | - |
| Q1 2021 | -1.51 | -1.50 | -0.53% | -31.30% | 500K | 1.159M | -56.86% | 150.00% |
| Q4 2020 | -1.50 | -1.30 | -15.52% | - | 400K | 2.372M | -83.14% | - |
| Q3 2020 | -1.32 | -1.21 | -9.22% | - | 100K | 2.066M | -95.16% | - |
| Q2 2020 | -1.30 | -0.97 | -34.71% | - | 18.488M | -100.00% | - | |
| Q1 2020 | -1.15 | -1.07 | -7.34% | - | 200K | 3.103M | -93.55% | - |
Notes
CRISPR THERAPEUTICS AG (CRSP) last reported earnings on 2/12/2026.
CRISPR THERAPEUTICS AG (CRSP) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, CRISPR THERAPEUTICS AG (CRSP) has beaten EPS estimates in 2 out of 4 releases.